Received Jun 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | UNK | — |
She states today he was given bexsero at the pharmacy; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 16-year-old male patient who received Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (received 1st dose of vaccine at age of 11 of batch number MCB4P). On 11-JUN-2025, the patient received the 2nd dose of Bexsero. On 11-JUN-2025, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too long (Verbatim: She states today he was given bexsero at the pharmacy). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-JUN-2025 The reporter was the mother of the patient. She stated his healthcare professional ordered a meningitis vaccine to be given. She stated that on the day of reporting he was given Bexsero at the pharmacy. The registered pharmacist who gave it stated he would need to come back for a Bexsero booster in 3 years only if he was in college. The patient received 2nd dose of Bexsero, later than the recommended interval, which led to lengthening of vaccination schedule.